脑脊液肌酸激酶BB同工酶:预测心脏骤停后结局的生物标志物
该回顾性队列研究纳入2010至2020年间三家医院收治的214例心脏骤停后仍昏迷、且在骤停后36至84小时检测脑脊液肌酸激酶BB同工酶(CSF CK-BB)的患者,其中83%接受了目标温度管理(TTM)。CSF CK-BB≥230 U/L预测出院时不良神经结局(CPC 4-5)的specificity为100%(95%CI 82-100%)、sensitivity为69%(95%CI 62-76%)。联合体感诱发电位(SSEP)双侧N20反应缺失后,specificity仍为100%,sensitivity提高至80%(95%CI 73-85%)。13例(9%)患者CK-BB与SSEP结果不一致。作者认为CSF CK-BB可成为心脏骤停后多模态神经预后评估的有用补充。
要点
- CSF CK-BB≥230 U/L预测出院时不良神经结局(CPC 4-5)的specificity为100%(95%CI 82-100%)、sensitivity为69%(95%CI 62-76%)。
- 联合SSEP双侧N20反应缺失后,specificity仍为100%,sensitivity提高至80%(95%CI 73-85%)。
- 214例患者中仅19例(9%)神经结局改善至CPC 1-3,提示该队列预后普遍不良。
- 13例(9%)患者CK-BB与SSEP结果不一致,提示单一指标可能遗漏或误判。
- CSF CK-BB检测时间窗为心脏骤停后36至84小时,适用于仍昏迷且接受TTM的患者。
适用人群与场景
- 2010至2020年收治于三家医院健康系统的心脏骤停后仍昏迷患者,且在骤停后36至84小时检测了CSF CK-BB。
- 214例 eligible 患者中,平均年龄54.7±4.8岁,72%为男性,33%为非白人,17%为可电击心律,90%为院外心脏骤停,83%接受了TTM。
诊断标准与关键阈值
- CSF CK-BB阈值230 U/L用于预测出院时不良神经结局(CPC 4-5)。
- 神经结局采用脑功能分类(CPC)评分:CPC 1-3为良好或中等结局,CPC 4-5为不良结局。
研究设计与关键结果
- 回顾性队列研究,纳入214例心脏骤停后仍昏迷且检测CSF CK-BB的患者,19例(9%)出院时神经结局改善至CPC 1-3。
- CSF CK-BB≥230 U/L预测出院时不良神经结局的specificity为100%(95%CI 82-100%)、sensitivity为69%(95%CI 62-76%)。
- 联合SSEP双侧N20反应缺失后,specificity仍为100%,sensitivity提高至80%(95%CI 73-85%)。
- 13例(9%)患者CK-BB与SSEP结果不一致。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为CSF CK-BB可成为心脏骤停后多模态神经预后评估的有用补充,CSF CK-BB阈值230 U/L在维持100% specificity的同时优化sensitivity至69%。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cerebrospinal fluid creatine kinase BB isoenzyme (CSF CK-BB) after cardiac arrest (CA) has been shown to have a high positive predictive value for poor neurological outcome, but it has not been evaluated in the setting of targeted temperature management (TTM) and modern CA care. We aimed to evaluate CSF CK-BB as a prognostic biomarker after CA.
METHODS: We performed a retrospective cohort study of patients with CA admitted between 2010 and 2020 to a three-hospital health system who remained comatose and had CSF CK-BB assayed between 36 and 84 h after CA. We examined the proportion of patients at hospital discharge who achieved favorable or intermediate neurological outcome, defined as Cerebral Performance Category score of 1-3, compared with those with poor outcome (Cerebral Performance Category score 4-5) for various CSF CK-BB thresholds. We also evaluated additive value of bilateral absence of somatosensory evoked potentials (SSEPs).
RESULTS: Among 214 eligible patients, the mean age was 54.7 ± 4.8 years, 72% of patients were male, 33% were nonwhite, 17% had shockable rhythm, 90% were out-of-hospital CA, and 83% received TTM. A total of 19 (9%) awakened. CSF CK-BB ≥ 230 U/L predicted a poor outcome at hospital discharge, with a specificity of 100% (95% confidence interval [CI] 82-100%) and sensitivity of 69% (95% CI 62-76%). When combined with bilaterally absent N20 response on SSEP, specificity remained 100% while sensitivity increased to 80% (95% CI 73-85%). Discordant CK-BB and SSEP findings were seen in 13 (9%) patients.
CONCLUSIONS: Cerebrospinal fluid creatine kinase BB isoenzyme levels accurately predicted poor neurological outcome among CA survivors treated with TTM. The CSF CK-BB cutoff of 230 U/L optimizes sensitivity to 69% while maintaining a specificity of 100%. CSF CK-BB could be a useful addition to multimodal neurological prognostication after CA.
参考来源
- Johnson NJ, Matin N, Singh A, et al. Cerebrospinal Creatine Kinase BB Isoenzyme: A Biomarker for Predicting Outcome After Cardiac Arrest. Neurocrit Care. 2024. PMID: 38955930. doi:10.1007/s12028-024-02037-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。